HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
By K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, O. Ringdén. Experimental Hematology, 2003
1,734 citations recorded by the source corpus.
Subfields: Genetics, Orthopedics and Sports Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/67d778f1e1c0451397154966fc91fad701420685
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Michael A. Matthay
- A. Caplan
- Jaehyup Kim
- P. Hematti
- O. Ringdén
- Lorraine O'Driscoll
- Frank Barry
- P. Vader
In Orthopedics and Sports Medicine
In Rheumatology
Citations in the corpus
- Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “However, upon stimulation with IFN-g or upon differentiation, MSCs can severely change their immunological properties and can express significantly more MHC class I and II molecules (108,283,284).”
- Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy (2012, background): “Mesenchymal stem cells are both immunoprivileged and immunosuppressive, thus bearing the potential to be used as an allograft.(8,11,29-33) To address potential advantages and disadvantages of allogeneic MSCs, we performed a randomized comparison of allografting vs autologous therapy in patients with”
- Why are MSCs therapeutic? New data: new insight (2009, background): “To support this suggestion, it was further documented that culture-expanded MSCs did not have MHC class II cell surface markers, but rather only MHC class I and no co-stimulator molecules [19].”
- Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung (2009, positive): “0001 Endotoxin 54,199 [30,995, 77,812] MSC 31,770 [16,272, 66,330] MSC CM 33,092 [2,636, 51,672] IL-10 (pg/ml) Control 0 [0, 0] 0.”
- Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages (2009, background): “In vitro studies using murine and human MSCs show these cells are capable of interacting with a plethora of immune cells in their different stages of activation, and modulating their responses through a variety of mechanisms [10-13].”
- The Tissue-Engineered Vascular Graft—Past, Present, and Future (2015, background): “Muscle-derived stem cells have been utilized in successful in vivo studies of TEVGs.74 When seeded onto PEUU scaffolds and implanted in rat aortas, these constructs demonstrated patency for up to 8 weeks, integrated with the surrounding tissue, and became populated with ECs and SMCs.”
- Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma (2006, background): “Finally, MSCs appear to be relatively nonimmunogenic (17), although the mechanism of their immune privilege is not well understood and is a subject of intense study (18, 19).”
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, background): “[51] Second, the use of fetal bovine serum for culturing MSCs has been criticized for potentially introducing zoonotic contamination to the cell product (e.”